NCI raises paylines, commemorates 50th anniversary of the National Cancer Act of 1971

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Pandemic notwithstanding, NCI is on track to reach the 15th percentile for the payline by 2025—a goal set by institute Director Ned Sharpless in response to a deluge of grant applications.

“Congress’s support has allowed NCI to raise the payline for R01 research awards by 35% since 2019. For two consecutive years, we’ve raised grant paylines for [early-stage investigators] as well,” Sharpless said Feb. 11 in his director’s report at a virtual meeting of the National Cancer Advisory Board.

Last year, Sharpless set the goal of reaching the 15th perentile by 2025.

“You can see the [Early Stage Investigator] payline is now 16th percentile. That is the best payline for an R01 out of the NCI in a very long time. And we are also able to sustain continuing awards at 100th percentile.”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.
Alexandria Carolan
Alexandria Carolan
Reporter
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login